ADIENNE Canadian Trademark Information

On Friday, June 28, 2013, a canadian trademark registration was filed for ADIENNE by ADIENNE S.r.l. *********, **********, ***** ****. The Canadian IP office has given the trademark application number of 1633077. The current status of this trademark filing is Registration published. The ADIENNE trademark is filed in the description of Pharmaceutical products, namely: pharmaceutical products used for conditioning treatment prior to haematopoietic progenitor cell transplantation and prior to haematopoietic stem cell transplantation, and for the treatment of haematological diseases such as leukaemia, lymphoma, multiple myeloma and thalassemia as well as tumours, in particular where allogenic or autologous haematopoietic progenitor cell transplantation is a treatment option , Antibodies used as pharmaceuticals preparations with anti-inflammatory action; monoclonal antibodies for neutralizing components of the complement system; pharmaceutical preparations for the prevention of ischemia/reperfusion injury associated with solid, organ transplantation; pharmaceutical preparations for treatment of graft-versus-host disease and severe aplastic anemia. , Pharmaceutical products, namely: pharmaceutical products used for conditioning treatment prior to haematopoietic progenitor cell transplantation and prior to haematopoietic stem cell transplantation, and for the treatment of haematological diseases such as leukaemia, lymphoma, multiple myeloma and thalassemia as well as tumours, in particular where allogenic or autologous haematopoietic progenitor cell transplantation is a treatment option , Antibodies used as pharmaceuticals preparations with anti-inflammatory action; monoclonal antibodies for neutralizing components of the complement system; pharmaceutical preparations for the prevention of ischemia/reperfusion injury associated with solid, organ transplantation; pharmaceutical preparations for treatment of graft-versus-host disease and severe aplastic anemia. , Antibodies used as pharmaceuticals preparations with anti-inflammatory action; monoclonal antibodies for neutralizing components of the complement system; pharmaceutical preparations for the prevention of ischemia/reperfusion injury associated with solid, organ transplantation; pharmaceutical preparations for treatment of graft-versus-host disease and severe aplastic anemia. , Pharmaceutical products, namely: pharmaceutical products used for conditioning treatment prior to haematopoietic progenitor cell transplantation and prior to haematopoietic stem cell transplantation, and for the treatment of haematological diseases such as leukaemia, lymphoma, multiple myeloma and thalassemia as well as tumours, in particular where allogenic or autologous haematopoietic progenitor cell transplantation is a treatment option , Antibodies used as pharmaceuticals products with anti-inflammatory action; monoclonal antibodies against complement components; pharmaceutical products for the prevention of ischemia/reperfusion injury associated with solid, organ transplantation; pharmaceutical products for treatment of graft-versus-host disease and severe aplastic anemia. , Antibodies used as pharmaceuticals preparations with anti-inflammatory action; monoclonal antibodies for neutralizing components of the complement system; pharmaceutical preparations for the prevention of ischemia/reperfusion injury associated with solid, organ transplantation; pharmaceutical preparations for treatment of graft-versus-host disease and severe aplastic anemia. , Antibodies used as pharmaceutical products with anti-inflammatory action; monoclonal antibodies against complement components; pharmaceutical products for the prevention of ischemia/reperfusion injury associated with solid organ transplantation; pharmaceutical products for treatment of graft-versus-host disease and severe aplastic anemia .